GLIMITERIS MV1 0.2

GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.

It is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.

Mechanism of Action

The therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:

1. Glimepiride (1 mg) – Sulfonylurea

• Stimulates insulin secretion by activating pancreatic beta cells.

• Provides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.

• Helps reduce both fasting and postprandial glucose levels.

2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor

• Delays the breakdown and absorption of carbohydrates in the intestine.

• Minimizes post-meal glucose spikes (PPBG).

• Acts locally in the gut and has minimal systemic absorption, which reduces systemic side effects.

3. Metformin Hydrochloride SR (500 mg) – Biguanide

• Decreases hepatic glucose production (gluconeogenesis).

• Improves peripheral insulin sensitivity, enhancing glucose uptake in muscles.

• Does not cause hypoglycemia on its own.

• The sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.

Indications

GLIMITERIS MV1 0.2 is indicated for:

• Adults with Type 2 Diabetes Mellitus.

• Patients inadequately controlled with monotherapy or dual therapy.

• Management of fasting and postprandial hyperglycemia.

• Long-term HbA1c reduction as part of a comprehensive diabetes care plan.

Key Benefits

✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.
✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.
✅ Reduced Pill Burden – Combines three medicines into a single tablet.
✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.
✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.
✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.

Dosage and Administration

• Recommended dose: One tablet once or twice daily with meals, or as directed by the physician.

• Administration tips:

  • Take with the first bite of a main meal to maximize Voglibose’s effect.

  • Swallow whole with water; do not crush or chew the SR tablet.

• Dose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.

Contraindications

GLIMITERIS MV1 0.2 is not suitable for patients with:

• Type 1 diabetes or diabetic ketoacidosis.

• Severe renal impairment (eGFR <30 mL/min/1.73 m²).

• Hepatic dysfunction.

• Severe gastrointestinal diseases.

• History of lactic acidosis.

• Hypersensitivity to Glimepiride, Voglibose, or Metformin.

• Pregnancy and lactation (unless strictly advised by a physician).

Warnings and Precautions

• Hypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.

• Lactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.

• GI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).

• Vitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.

• Liver and Kidney Function: Regular monitoring is recommended for safe long-term use.

Adverse Effects

Common:

• Glimepiride: Mild hypoglycemia, dizziness, slight weight gain.

• Voglibose: Gas, abdominal discomfort, mild diarrhea.

• Metformin SR: Nausea, bloating, metallic taste, loose stools.

Rare but Serious:

• Lactic acidosis (from Metformin).

• Severe hypoglycemia (especially if meals are skipped).

• Allergic reactions such as rash, itching, or swelling.

• Elevated liver enzymes.

Seek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.

Drug Interactions

• Increased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.

• Reduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.

• Lactic acidosis risk: Higher with alcohol or iodinated contrast agents. 

If You Need More Information About EMPATECH 10 Tablet: Click here